Vanguards of Health Care by Bloomberg Intelligence
Vericel Advances Use of Cell Therapies
10 May 2024
Vericel acquired a hidden gem in cartilage repair that other companies had written off, and developed it into a high-growth product that could potentially address a $4 billion market. In this episode of the Vanguards of Health Care podcast, Vericel CEO Nick Colangelo sits down with Matt Henriksson, Bloomberg Intelligence analyst, to talk about how MACI took over as the market leader for cartilage repair in the knee and its potential to do so for the ankle. Colangelo also discusses why the company built a diversified portfolio and how NexoBrid complements its Epicel platform to fill out the company’s burn-care offerings.See omnystudio.com/listener for privacy information.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Vanguards of Health Care by Bloomberg Intelligence
Transcribed and ready to explore now
Aegis Ventures’ Blueprint for Building AI-Native Companies
04 Dec 2025
Vanguards of Health Care by Bloomberg Intelligence
Beta Bionics Does the Work to Reduce Insulin Pump Burden
20 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Fosun Pharma’s Drive Beyond China
17 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
ARS Pharma’s Clinical Differentiation
13 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Biolinq Introduces New Silicon Tech Opens Next Chapter of Glucose and Analyte Detection
06 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates
27 Oct 2025
Vanguards of Health Care by Bloomberg Intelligence